Ys Biopharma Co Stock Alpha and Beta Analysis

YS Stock   0.41  0.02  5.13%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as YS Biopharma Co. It also helps investors analyze the systematic and unsystematic risks associated with investing in YS Biopharma over a specified time horizon. Remember, high YS Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to YS Biopharma's market risk premium analysis include:
Beta
0.53
Alpha
(0.62)
Risk
6.34
Sharpe Ratio
(0.08)
Expected Return
(0.49)
Please note that although YS Biopharma alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., NYSE Composite index.) So in this particular case, YS Biopharma did 0.62  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of YS Biopharma Co stock's relative risk over its benchmark. YS Biopharma has a beta of 0.53  . As returns on the market increase, YS Biopharma returns are expected to increase less than the market. However, during the bear market, the loss on holding YS Biopharma will be expected to be smaller as well. At this time, YS Biopharma's Book Value per Share is comparatively stable as compared to the past year. Price to Book Value is likely to gain to 0.25 in 2024, whereas Enterprise Value over EBITDA is likely to drop (1.77) in 2024.

Enterprise Value

415.19 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out YS Biopharma Backtesting, YS Biopharma Valuation, YS Biopharma Correlation, YS Biopharma Hype Analysis, YS Biopharma Volatility, YS Biopharma History and analyze YS Biopharma Performance.

YS Biopharma Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. YS Biopharma market risk premium is the additional return an investor will receive from holding YS Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in YS Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate YS Biopharma's performance over market.
α-0.62   β0.53

YS Biopharma expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of YS Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how YS Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

YS Biopharma Market Price Analysis

Market price analysis indicators help investors to evaluate how YS Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading YS Biopharma shares will generate the highest return on investment. By understating and applying YS Biopharma stock market price indicators, traders can identify YS Biopharma position entry and exit signals to maximize returns.

YS Biopharma Return and Market Media

The median price of YS Biopharma for the period between Fri, Nov 24, 2023 and Thu, Feb 22, 2024 is 0.51 with a coefficient of variation of 15.3. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 0.5, and mean deviation of 0.06. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
YS Biopharma Change of Independent Director - Form 6-K - Marketscreener.com
12/12/2023
2
YS Biopharma Says Fake Press Release Called for Extraordinary General Meeting
12/20/2023
3
YS Biopharma ANY OTHER PERSON WHO KNOWS OF THIS ORDER AND DOES ANYTHING WHICH HELPS OR ... - Marketscreener.com
12/28/2023
4
Other
01/08/2024
5
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
01/22/2024
6
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
02/08/2024
7
YS Biopharma announces 40M private placement
02/09/2024
8
YS Biopharma Announces Appointment of New Directors
02/14/2024
9
Unclassified Event
02/15/2024

About YS Biopharma Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including YS Biopharma or other stocks. Alpha measures the amount that position in YS Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

YS Biopharma Upcoming Company Events

As portrayed in its financial statements, the presentation of YS Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, YS Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of YS Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of YS Biopharma. Please utilize our Beneish M Score to check the likelihood of YS Biopharma's management manipulating its earnings.
22nd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Build Portfolio with YS Biopharma

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
YS Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of YS Biopharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of YS Biopharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...